Detalhe da pesquisa
1.
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Br J Haematol
; 192(3): 504-513, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621535
2.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Br J Haematol
; 192(6): 1015-1019, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436212
3.
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Br J Haematol
; 175(4): 668-672, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27477167
4.
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.
Blood Adv
; 6(7): 2414-2426, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34700343
5.
Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
Bone Marrow Transplant
; 55(4): 840, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862820
6.
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
EJHaem
; 1(1): 133-141, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35847742
7.
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
Blood Adv
; 3(24): 4264-4270, 2019 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869413
8.
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
Bone Marrow Transplant
; 54(3): 465-468, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30104718